From the Gastroenterology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston. Address reprint requests to Dr. Kelly at Dana 601, Gastroenterology BIDMC, 330 Brookline Ave., Boston, MA 02215.
Supported in part by grants (RO1-AI 53069, to Dr. Kelly; and R37-DK 03458, to Dr. LaMont) from the National Institutes of Health.
Dr. Kelly reports receiving consulting fees from Acambis, Actelion, BioHelix, Genzyme, Replidyne, Salix, and ViroPharma and grant support from Actelion and Genzyme and serving as an expert witness in legal cases related to C. difficile infection. No other potential conflict of interest relevant to this article was reported.
